Pingyangmycin-regulated expressions of adhesion molecules in human venous malformation endothelial cells

Abstract

Pingyangmycin (bleomycin A5 hydrochloride, PYM) is one of the anti-neoplastic agents which have been commonly used to treat venous malformations. However, the underlying mechanism by which PYM treats venous malformations remains poorly understood. It was reported that venous endothelial cells could recruit neutrophils via adhesion molecules (E-selectin, ICAM-1, ICAM-3, VCAM-1) during the acute/chronic inflammation and subsequent histological fibrosis after sclerotherapy with PYM. This study explored if the expression of E-selectin, ICAM-1, ICAM-3 and VCAM-1 in human venous malformation endothelial cells could be affected by PYM. HVMECs were cultured from human venous malformation tissue. Expressions of E-selectin, ICAM-1, ICAM-3 and VCAM-1 on HVMECs in response to PYM were analyzed by cell ELISA. The relative levels of mRNA expression in the cells were semi-quantified. The results showed that PYM up-regulated the expressions of E-selectin, ICAM-3, VCAM-1 and ICAM-1 in both time- and concentration-dependent manner. Our findings suggested that PYM could induce the expression of adhesion molecules in HVMECs, which might be a possible mechanism by which sclerotherapy by intralesional injection of PYM treats venous malformations.

Keywords

E-selectin / intercellular adhesion molecule-1 / intercellular adhesion molecule-3 / vascular cell adhesion molecule-1 / cell culture

References

[1] BerenguerB., BurrowsP.E., ZurakowskiD., et al.. Sclerotherapy of craniofacial venous malformations: complications and results. Plast Reconstr Surg, 1999, 104(1): 1-11

[2] KimK.H., SungM.W., RohJ.L., et al.. Sclerotherapy for congenital lesions in the head and neck. Otolaryngol Head Neck Surg, 2004, 131(3): 307-316

[3] WeiZ.J.. Sclerotherapy of maxillofacial venous malformations. J Oral Maxillofac Surg, 2010, 68(6): 1456-1457

[4] ZhengJ.W.. Percutaneous sclerotherapy of massive venous malformations of the face and neck using fibrin glue combined with OK-432 and pingyangmycin. Head Neck, 2010, 32(6): 826-827

[5] HouR., GuoJ., HuK., et al.. A clinical study of ultrasound-guided intralesional injection of bleomycin A5 on venous malformation in cervical-facial region in China. J Vasc Surg, 2010, 51(4): 940-945

[6] MathurN.N., RanaI., BothraR., et al.. Bleomycin sclerotherapy in congenital lymphatic and vascular malformations of head and neck. Int J Pediatr Otorhinolaryngol, 2005, 69(1): 75-80

[7] SanlialpI., KarnakI., TanyelF.C., et al.. Sclerotherapy for lymphangioma in children. Int J Pediatr Otorhinolaryngol, 2003, 67(7): 795-800

[8] IzbickiG., SegelM.J., ChristensenT.G., et al.. Time course of bleomycin-induced lung fibrosis. Int J Exp Pathol, 2002, 83(3): 111-119

[9] AzumaA., TakahashiS., NoseM., et al.. Role of E-selectin in bleomycin induced lung fibrosis in mice. Thorax, 2000, 55(2): 147-152

[10] HamaguchiY., NishizawaY., YasuiM., et al.. Intercellular adhesion molecule-1 and L-selectin regulate bleomycin-induced lung fibrosis. Am J Pathol, 2002, 161(5): 1607-1618

[11] LiY.J., AzumaA., TakahashiS., et al.. Fourteen-membered ring macrolides inhibit vascular cell adhesion molecule 1 messenger RNA induction and leukocyte migration: Role in preventing lung injury and fibrosis in bleomycin-challenged Mice. Chest, 2002, 122(6): 2137-2145

[12] SatoN., SuzukiY., NishioK., et al.. Roles of ICAM-1 for abnormal leukocyte recruitment in the microcirculation of bleomycin-induced fibrotic lung injury. Am J Respir Crit Care Med, 2000, 161(5): 1681-1688

[13] ZhaoJ.H., ZhangW.F., ZhaoY.F.. Sclerotherapy of oral and facial venous malformations with use of pingyangmycin and/or sodium morrhuate. Int J Oral Maxillofac Surg, 2004, 33(5): 463-466

[14] ZhengJ.W., YangX.J., WangY.A., et al.. Intralesional injection of Pingyangmycin for vascular malformations in oral and maxillofacial regions: an evaluation of 297 consecutive patients. Oral Oncol, 2009, 45(10): 872-876

[15] ZhaoJ.H., ZhaoY.F., ZhangW.F.. Histological investigation of Veins and venous malformations after injection of sclerosing agents. Asian J Oral Maxillofac Surg, 2002, 14(2): 226-231

[16] JiaJ., ZhaoY.F., ZhangW.F., et al.. Isolation, culture and identification of human venous malformation endothelial cells. Zhonghua Kou Qiang Yi Xue Za Zhi (Chinese), 2002, 37(4): 284-286

[17] HaraldsenG., KvaleD., LienB., et al.. Cytokine-regulated expression of E-selectin, intercellular adhesion molecule-1 (ICAM-1), and vascular cell adhesion molecule-1 (VCAM-1) in human microvascular endothelial cells. J Immunol, 1996, 156(7): 2558-2565

[18] MiyamotoH., SugawaraI., AzumaA., et al.. Differential secretion of cytokines and adhesion molecules by HUVEC stimulated with low concentrations of bleomycin. Cell Immunol, 2002, 219(2): 73-81

[19] AmraniY., LazaarA.L., HoffmanR., et al.. Activation of p55 tumor necrosis factor-β receptor-1 coupled to tumor necrosis factor receptor-associated factor 2 stimulates intercellular adhesion molecule-1 expression by modulating a thapsigargin-sensitive pathway in human tracheal smooth muscle cells. Mol Pharmacol, 2000, 58(1): 237-245

[20] ScholzD., DevauxB., HircheA., et al.. Expression of adhesion molecules is specific and time-dependent in cytokine-stimulated endothelial cells in culture. Cell Tissue Res, 1996, 284(3): 415-423

[21] BinnsR.M., LicenceS.T., HarrisonA.A., et al.. In vivo E-selectin upregulation correlates early with infiltration of PMN, later with PBL entry: MAbs block both. Am J Physiol, 1996, 270(1Pt2): 183-193

[22] MarlinS.D., SpringerT.A.. Purified intercellular adhesion molecule-1 (ICAM-1) is a ligand for lymphocyte function-associated antigen 1 (LFA-1). Cell, 1987, 51(5): 813-819

[23] DustinM.L., RothleinR., BhanA.K., et al.. Induction by IL-1 and interferon-α: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J Immunol, 2011, 186(9): 5024-5033

[24] KasperM., KoslowskiR., LutherT., et al.. Immunohistochemical evidence for loss of ICAM-1 by alveolar epithelial cells in pulmonary fibrosis. Histochem. Cell Biol, 1995, 104(5): 397-405

[25] MatsuseT., TeramotoS., KatayamaH., et al.. ICAM-1 mediates lung leukocyte recruitment but not pulmonary fibrosis in a murine model of bleomycin-induced lung injury. Eur Respir J, 1999, 13(1): 71-77

[26] FichtnerF., KoslowskiR., AugsteinA., et al.. Bleomycin induces IL-8 and ICAM-1 expression in microvascular pulmonary endothelial cells. Exp Toxicol Pathol, 2004, 55(6): 497-503

[27] LeeuwenbergJ.F., SmeetsE.F., NeefjesJ.J., et al.. E-selectin and intercellular adhesion molecule-1 are released by activated human endothelial cells in vitro. Immunology, 1992, 77(4): 543-549

[28] CinesD.B., PollakE.S., BuckC.A., et al.. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood, 1998, 91(10): 3527-3561

[29] VazeuxR., HoffmanP.A., TomitaJ.K., et al.. Cloning and characterization of a new intercellular adhesion molecule ICAM-R. Nature, 1992, 360(6403): 485-488

[30] PateyN., VazeuxR., CanioniD., et al.. Intercellular adhesion molecule-3 on endothelial cells. Expression in tumors but not in inflammatory responses. Am J Pathol, 1996, 148(2): 465-472